Home » Healthcare » Pharmaceuticals » Bronchitis Treatment Market

Bronchitis Treatment Market By Type Of Drug Class (Antitussives/ Expectorants, Bronchodilators, Beta-Adrenergic Agonist, Systemic Corticosteroids, Inhaled Corticosteroids, Phosphodiesterase-4 Inhibitors, Analgesics, Antibiotics) – Growth, Future Prospects, Competitive Analysis, 2018 – 2026

Summary
Table Of Content

Industry Outlook

The bronchitis treatment market had a market value of US$ 3,345.8 million in 2017 and is expected to grow at a CAGR of 4.9% between 2018 and 2026. The bronchitis treatment market is growing gradually throughout the forecast period due to a strong product pipeline equipped with target-specific drugs and rising prevalence and awareness related to the treatment and diagnosis of bronchitis. The major cause of bronchitis is frequent cigarette smoking, coupled with exposure to air pollutants. As a result, the overall growth of global bronchitis treatment is significant and is expected to continue throughout the forecast year, thanks to upcoming drugs currently undergoing trials.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Synopsis

Continuous research and development in the field of bronchitis treatment are expected to bring novel drugs to the market and ultimately assist the overall growth of the industry.

During the forecast period from 2018 to 2026, phosphodiesterase-4 inhibitors were identified as the fastest-growing segment due to major factors such as the fact that Roflumilast is beneficial in chronic bronchitis to decrease exacerbations and relieve dyspnea, and physicians treat chronic bronchitis on a priority basis as it is more complex compared to acute bronchitis. Roflumilast also plays a key role in improving lung function and assisting the recovery of patients. Thus, novel drugs entering the market will increase the growth of the overall bronchitis treatment market, as there is huge market demand for target-specific drugs.

Increasing prevalence and awareness related to bronchitis in Asia-Pacific make it the fastest-growing region throughout the forecast period.

The Asia Pacific will grow significantly throughout the forecast period from 2018 to 2026. The key factors responsible for the growth of the bronchitis treatment market in this region are the rising prevalence of bronchitis due to high levels of air pollution and smoking and increasing awareness and accessibility related to bronchitis treatment. There are several awareness campaigns carried out by the government and non-government organizations in developing countries in the Asia Pacific, such as China, India, Indonesia, and Thailand, due to which the bronchitis treatment market is growing significantly in this region. China and India have the highest rates of bronchitis, which is primarily due to air pollution and their large cigarette-smoking populations. According to the World Health Organization (WHO), it has been recorded that in Asia, around one-third, or 2.2 million, of the world’s 7 million premature deaths occur due to respiratory disorders caused by air pollution each year.

Periods of History and Forecast

The bronchitis treatment market was analyzed considering current market trends for the base year of 2017, and based on future trends, CAGRs were calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

This report provides an in-depth analysis related to the bronchitis treatment market, covering market elucidations and assumptions based on in-depth qualitative and quantitative data collected through primary and secondary research. Stakeholders in the industry have helped analyze and study market dynamics such as drivers, opportunities, and challenges, which have been further concentrated at the regional and country levels. This report also includes a comprehensive analysis of the global bronchitis treatment market, segmented by type of drug and geography. The report also gives information related to the competitive landscape of the major players present and operating in the bronchitis treatment market that covers in-depth company information such as the latest business strategies, financial data, and product profiles.

The key manufacturers present in the market were reported based on their product portfolios, current market updates, financial information, and key strategies. This report also includes attractive investment propositions studied with the aid of PESTEL analysis, which is based on detailed geographical research. Major companies studied in the overall report are AstraZeneca Plc, DVB Technologies SA, F. Hoffmann-La Roche Ltd., Han Wha Pharma Co. Ltd., and Mucositis BV, among others.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key questions are answered in this report.

Which is the trending drug class type in the market preferred for bronchitis treatment, and why?
What are the current market strategies and policies that key companies are planning and implementing, as well as the competitive landscape of the bronchitis treatment market?
Which are the important and potential geographical markets (regions and countries) in the bronchitis treatment market?
Which is the largest and fastest-growing region globally?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global BT Market Portraiture
2.2. Global BT Market, by Type of Drug Class, 2017 (US$ Mn)
2.3. Global BT Market, by Geography, 2017 Vs 2026 (Value %)

Chapter 3. Global Bronchitis Treatment (BT) Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.2.1. Increasing prevalence and awareness related to bronchitis in developed as well as developing countries
3.2.2. Rising cases of respiratory diseases triggered due to air-pollutants or cigarette smoke
3.3. Challenges
3.3.1. Initial stages of bronchitis are most of the times treated with traditional medicines in Asia Pacific
3.4. Opportunities
3.4.1. Strong pipeline and continuous research and development in the field of BT
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2017

Chapter 4. Global Bronchitis Treatment (BT) Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Antitussives/ Expectorants
4.3. Bronchodilators
4.4. Beta-adrenergic Agonist
4.5. Systemic Corticosteroids
4.6. Inhaled Corticosteroids
4.7. Phosphodiesterase-4 Inhibitors
4.8. Analgesics
4.9. Antibiotics

Chapter 5. Global Bronchitis Treatment (BT) Market: Pipeline Analysis
5.1. Overview
5.2. Phase III [Till 2026] (U$ Mn)
5.2.1. Extracorporeal Photopheresis (ECP)
5.2.2. Cyclosporine
5.3. Phase II (Qualitative Information)
5.3.1. Alteplase
5.3.2. Alvelestat
5.3.3. CKD-497
5.3.4. Treatment-inhaled tPA
5.4. Phase I (Qualitative Information)
5.4.1. HOB-051
5.4.2. Pirfenidone
5.4.3. Aerosolized Infasurf

Chapter 6. Global Bronchitis Treatment (BT) Market, by Geography, 2016 – 2026 (US$ Mn)
6.1. Overview
6.2. North America BT Market Analysis, 2016 – 2026
6.2.1. North America BT Market, by Type of Drug Class, 2016–2026 (US$ Mn)
6.2.2. North America BT Market, by Country, 2016 – 2026 (US$ Mn)
6.2.2.1. U.S.
6.2.2.2. Canada
6.3. Europe BT Market Analysis, 2016 – 2026
6.3.1. Europe BT Market, by Type of Drug Class, 2016–2026 (US$ Mn)
6.3.2. Europe BT Market, by Country, 2016 – 2026 (US$ Mn)
6.3.2.1. U.K.
6.3.2.2. Germany
6.3.2.3. Rest of Europe
6.4. Asia Pacific BT Market Analysis, 2016 – 2026
6.4.1. Asia Pacific BT Market, by Type of Drug Class, 2016–2026 (US$ Mn)
6.4.2. Asia Pacific BT Market, by Country, 2016 – 2026 (US$ Mn)
6.4.2.1. Japan
6.4.2.2. China
6.4.2.3. Rest of APAC
6.5. Latin America BT Market Analysis, 2016 – 2026
6.5.1. Latin America BT Market, by Type of Drug Class, 2016–2026 (US$ Mn)
6.5.2. Latin America BT Market, by Country, 2016 – 2026 (US$ Mn)
6.5.2.1. Brazil
6.5.2.2. Mexico
6.5.2.3. Rest of Latin America
6.6. Middle East & Africa (MEA) BT Market Analysis, 2016 – 2026
6.6.1. Middle East & Africa BT Market, by Type of Drug Class, 2016–2026 (US$ Mn)
6.6.2. MEA BT Market, by Region, 2016 – 2026 (US$ Mn)
6.6.2.1. GCC
6.6.2.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Advanced Inhalation Therapies (AIT) Ltd.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. AstraZeneca Plc
7.3. DBV Technologies SA
7.4. F. Hoffmann-La Roche Ltd.
7.5. Han Wha Pharma Co. Ltd.
7.6. Kyorin Pharmaceutical Co Ltd.
7.7. Merck & Co.
7.8. Mucosis BV
7.9. Orbis Biosciences, Inc.
7.10. Therabron Therapeutics, Inc.
7.11. GlaxoSmithKline plc
7.12. Chong Kun Dang Pharmaceutical
7.13. ONY Biotech Inc.
7.14. Genentech, Inc.
7.15. Daewon Pharm Co. Ltd.

List of Figures

FIG. 1 : Bronchitis Treatment (BT): Market Segmentation
FIG. 2 : Global BT Market Share, by Type of Drug Class, 2017 (US$ Mn)
FIG. 3 : Global BT Market, by Geography, 2017 Vs 2026 (Value %)
FIG. 4 : Attractive Investment Proposition, by Geography, 2017
FIG. 5 : Market Competition Landscape, by Key Players, 2017
FIG. 6 : Global Antitussives/expectorants Market for BT, 2016 – 2026 (US$ Mn)
FIG. 7 : Global Bronchodilators Market for BT, 2016 – 2026 (US$ Mn)
FIG. 8 : Global Beta-adrenergic Agonist Market for BT, 2016 – 2026 (US$ Mn)
FIG. 9 : Global Systemic Corticosteroids for BT Market, 2016 – 2026 (US$ Mn)
FIG. 10 : Global Inhaled Corticosteroids for BT Market, 2016 – 2026 (US$ Mn)
FIG. 11 : Global Phosphodiesterase-4 Inhibitors Market for BT, 2016 – 2026 (US$ Mn)
FIG. 12 : Global Analgesics Market for BT, 2016 – 2026 (US$ Mn)
FIG. 13 : Global Antibiotics Market for BT, 2016 – 2026 (US$ Mn)
FIG. 14 : Global Cyclosporine Market for BT, till 2026 (US$ Mn)
FIG. 15 : Global Extracorporeal Photopheresis (ECP) Market for BT, till 2026 (US$ Mn)
FIG. 16 : U.S. BT Market, 2016 – 2026 (US$ Mn)
FIG. 17 : Canada BT Market, 2016 – 2026 (US$ Mn)
FIG. 18 : U.K. BT Market, 2016 – 2026 (US$ Mn)
FIG. 19 : Germany BT Market, 2016 – 2026 (US$ Mn)
FIG. 20 : Rest Of Europe BT Market, 2016 – 2026 (US$ Mn)
FIG. 21 : Japan BT Market, 2016 – 2026 (US$ Mn)
FIG. 22 : China BT Market, 2016 – 2026 (US$ Mn)
FIG. 23 : Rest Of Asia Pacific BT Market, 2016 – 2026 (US$ Mn)
FIG. 24 : Brazil BT Market, 2016 – 2026 (US$ Mn)
FIG. 25 : Mexico BT Market, 2016 – 2026 (US$ Mn)
FIG. 26 : Rest Of Latin America BT Market, 2016 – 2026 (US$ Mn)
FIG. 27 : GCC BT Market, 2016 – 2026 (US$ Mn)
FIG. 28 : Rest Of Middle East And Africa BT Market, 2016 – 2026 (US$ Mn)

List of Tables

TABLE 1 : Global Bronchitis Treatment (BT) Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
TABLE 2 : North America BT Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
TABLE 3 : North America BT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 4 : Europe BT Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
TABLE 5 : Europe BT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 6 : Asia Pacific BT Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
TABLE 7 : Asia Pacific BT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 8 : Latin America BT Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
TABLE 9 : Latin America BT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 10 : Middle East & Africa BT Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
TABLE 11 : Middle East And Africa BT Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 12 : Advanced Inhalation Therapies (AIT) Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 13 : AstraZeneca Plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 14 : DBV Technologies SA: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 : F. Hoffmann-La Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 : Han Wha Pharma Co. Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 : Kyorin Pharmaceutical Co Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 : Merck & Co.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 : Mucosis BV: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 : Orbis Biosciences, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 : Therabron Therapeutics, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 : GlaxoSmithKline plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 : Chong Kun Dang Pharmaceutical: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 24 : ONY Biotech Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 25 : Genentech, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 26 : Daewon Pharm Co. Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)

Frequently Asked Questions

What is the size of Bronchitis Treatment Market?

The market for Bronchitis Treatment Market is expected to reach At US$ 3,345.8 Mn in 2026.

What is the Bronchitis Treatment Market CAGR?

The Bronchitis Treatment Market is expected to see significant CAGR growth over the coming years, at 4.9%.

What is the Forecast period considered for Bronchitis Treatment Market?

The report is forecasted to 2018-2026

What is the base year considered for Bronchitis Treatment Market?

The base year of this report is 2017.

Who are the major players in this market?

Advanced Inhalation Therapies (AIT) Ltd., Financial Information (Subject to data availability),Product Portfolio,F. Hoffmann-La Roche Ltd., Han Wha Pharma Co. Ltd. are some of the major players in the global market.

Purchase Options

Single User

$4699

Multi User

$5699

Custom Report

$7699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –